期刊文献+

Fas、FasL在非小细胞肺癌中的表达及其与肿瘤免疫和细胞凋亡的关系 被引量:16

Expression of Fas/FasL protein and its relationship with tumorigenesis immunology and apoptosis in non-small cell lung cancer
下载PDF
导出
摘要 目的为探讨Fas/FasL系统在非小细胞肺癌(NSCLC)发生发展中所起的免疫逃逸作用,为临床早期诊断肺癌、判断预后、设计新的治疗策略提供依据。方法采用免疫组织化学方法检测Fas、FasL在NSCLC组织及正常肺组织中的表达,同时采用抗CD45RO抗体检测肿瘤组织中浸润淋巴细胞(TIL)的数量,应用TUNEL技术检测肺癌细胞凋亡。结果 Fas在肺癌组织低表达并存在异位表达,表达率与细胞分化有关;FasL在肺癌组织中高表达,表达率和细胞类型及淋巴结转移相关,与TIL浸润程度呈负相关,Fas表达与肺癌细胞凋亡水平无关。结论 NSCLC肺癌组织中普遍存在Fas表达的下调、异位表达及FasL高表达,导致癌细胞的免疫逃逸,参与NSCLC的发生和发展。 Objective In order to provide evidence for early diagnosis,prognosis prediction and new treatment of lung cancer,we analyze the immune escape of the Fas/FasL system in the carcinogenesis and progress of non-small cell lung cancer(NSCLC).Methods Immunohisochemistry(IHC) method was used to determine the expression of Fas/FasL protein in NSCLC and normal lung tissues;CD45RO antibody and TUNEL technique were used to detect the tumor infiltrating lymphocytes(TILs) and apoptosis respectively.Results Fas expression was found to be significantly reduced in cancer tissues,and it was correlated with the degree of tissue differentiation.There was a high level of FasL expression in cancer tissues.The expression rate of FasL was correlated with the cell type and lymph node metastasis,and negatively correlated with TIL infiltration degree.Fas expression had no association with the apoptosis level of cancer cells.Conclusion Reduced or absent expression of Fas and increased FasL expression are common in NSCLC tissues,which leads to the escape of cancer cells from immunosurveillance and thus the carcinogenesis and development of NSCLC.
出处 《西安交通大学学报(医学版)》 CAS CSCD 北大核心 2011年第1期6-9,共4页 Journal of Xi’an Jiaotong University(Medical Sciences)
关键词 FAS/FASL 肿瘤组织中浸润淋巴细胞 免疫组化 CD45RO 非小细胞肺癌 细胞凋亡 TUNEL 免疫逃逸 Fas/FasL CD45RO tumor infiltrating lymphocyte immunohistochemistry non-small cell lung cancer apoptosis TUNEL immune escape
  • 相关文献

参考文献14

  • 1O'CONNELL J, BENNETT MW, O'SULLIVAN GC, et al. The Fas counterattack: cancer as a site of immune privilege [J]. Immunol Today, 1999, 20(1) :46-52.
  • 2SCHIMONISHI T, ISSE K, SHIBATA F, et al. Up-regulation of fas ligand at early stages and down-regulation of Fas at progressed stages of introhepatic cholangiocareinoma reflect evasion from immune surveillance [J].Hepatology, 2000, 32(4) : 761-762.
  • 3CHANG MY, CHONG IW, CHEN FM, et al. High frequency of frameshift mutation on p53 gene in Taiwan Residents with non small cell lung cancer [J]. Cancer Lett, 2005, 222(2):195-204.
  • 4SCHEIDER-STOCK R, MAWRIN C, MOTSCH C, et al. Retention of the arginine allele in codon 72 of the p53 gene correlates with poor apoptosis in head and neck cancer[J]. Am J Pathol, 2004, 164(4) :1233-1241.
  • 5KOCH M, BECKHOVE P, DEN WINKEL JO, et al. Tumor infiltrating T lymphocytes in colorectal cancer : Tumor-selective activation and cytotoxic activity in situ [J]. Ann Surg, 2006, 244(6) :986-992.
  • 6朱强,邓长生.结肠癌细胞通过Fas/FasL诱导淋巴细胞发生凋亡[J].癌症,2002,21(3):272-275. 被引量:6
  • 7ZHANG J, XU G. Suppression of FasL expression in tumor ceils and preventing tumor necrosis factor-induced apoptosis by adenovirus 14.7K is an effective escape mechanism for immune cells [J].Cancer Genet Cytogenet, 2007, 179(2):112-117.
  • 8PRETSCHER D, DISTEL LV, GRABENBAUER GG, et al. Distribution of immune cells in head and neck cancer: CD8+ T-cells and CD20+ B-cells in metastatic lymph nodes are associated with favourable outcome in patients with oro- and hypopharyngeal carcinoma[J].BMC Cancer, 2009, 22(9) :292.
  • 9ENAMI A, TSUTSUMI K, KOBAUASHI T, et al. Correlation between Fas/Fas-ligand expression and apoptosis in undifferentiated nasopharyngeal carcinoma [J].Nippon Jibiinkoka Gakkai Kaiho, 2002, 105(10) :1087-1092.
  • 10O'CONNELL J, BENNETT MW, O'SULLIVAN GC, et al. The Fas counterattack: a molecular mechanism of tumor immune privilege [J]. MotMed, 1997, 3(5)294-300.

二级参考文献5

  • 1O'Connell J,Bennett M W,O'Sullivan G C, et al. Expression of Fas (CD95/APO-1) ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer [J]. Gut,1999,44:156-162.
  • 2Connell J O, Bennett M W, Sullivan G C O, et al. Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer [J]. J Pathol,1998,186:240-246.
  • 3Shiraki K, Tsuj N, Shiode T, et al. Expression of Fas ligand in liver metastasis of human colonic adenocarcinomas [J]. Proc Natl Acad Sci USA, 2000,94:6420-6425.
  • 4Cstherine G, Yasuo T, Christoph B, et al. Up-regulation of Fas(Apo-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer [J]. Cancer Research, 1998, 58:2057-2062.
  • 5Gloria A N, Thomas B, Sandra P F, et al. human lung carcinomas express Fas ligand [J]. Cancer Research,1997,57:1007-1012.

共引文献5

同被引文献218

引证文献16

二级引证文献105

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部